GENERICS - BROAD AND DIVERSIFIED PORTFOLIO
Leveraging our pre-eminent platform in Hong Kong, we have cemented our position as a generics market leader in a large and growing number of therapeutic categories. We have built a broad and diversified portfolio that can offer a comprehensive suite of generic drugs, including cardiovascular, respiratory, anti-infectives, anti-depressants, anti-psychotics, oral anti-diabetic drugs, providing a one-stop solution for healthcare professionals in both public and private sectors.
LEADERSHIP IN PUBLIC HOSPITALS
Central Nervous System
LEADERSHIP IN PRIVATE SECTOR
- Scar Treatment
- Vitamins and Minerals
PROPRIETARY MEDICINE BRANDS AND PRODUCTS
Tong Tai Chung -
Flying Eagle Woodlok Oil
Ho Chai Kung Tji Thung San
INTERNATIONAL BRANDS IN HONG KONG
We leverage our strong market presence and extensive sales and brand management capabilities in our representation of pharmaceutical and biotech products from reputable multi-national companies, thus further enhancing the breadth of our product portfolio. Through these professional partnerships, we strive to create synergies which will add value to our partners while in pursuit of business opportunities and growth.
We represent the following leading brands and products like Merz (Germany) for Contractubex and 3M for Littmann Stethoscope:
R&D AND COLLABORATIONS
A leader in pharmaceutical research and development in Hong Kong, our in-house research and development team developed over 30%* of the new drugs registered by generic drug manufacturers in Hong Kong from 2013 to 2015. We aim to develop premium generics based on our established product development know-how and deep market insight.
Focusing on specialized formulations and having acquired specific manufacturing skills and know-how for certain difficult-to-make products, such as controlled-release formulations, sterile products, suppositories and enemas, we possess a host of drug registrations with unique formulae allowing us to command a competitive position in certain selected segments of market.
Our current research and development team cooperates closely with a panel of formulation scientists and research institutions both locally and abroad. Our connections with research institutions and university hospitals also enhance our competence in both formulation and clinical pursuits.
* Industry report by Frost & Sullivan 2015
GENERIC DRUGS R&D
IN HONG KONG
We have entered into a collaboration agreement with the Hong Kong Institute of Biotechnology on establishing a new research and development center which will be equipped with advanced facilities for the development of formulation and coating technologies to be applied on premium generics and proprietary Chinese medicines. The center is targeted for completion by the end of 2016.